Location History:
- Thane, IN (2008 - 2010)
- Mumbai, IN (2015)
- Maharashtra, IN (2009 - 2016)
Company Filing History:
Years Active: 2008-2016
Title: Innovative Contributions of Dharmendra Singh in Pharmaceutical Patents
Introduction: Dharmendra Singh, a noted inventor based in Maharashtra, India, has made significant contributions to the field of pharmaceuticals. With a total of seven patents to his name, his work focuses on enhancing drug formulations, particularly in treating parasitic infections.
Latest Patents: Singh's latest patents showcase his dedication to improving pharmaceutical compositions. One of his notable inventions involves a novel pharmaceutical composition that enhances bioavailability through improved aqueous dissolution of poorly water-soluble drugs. Specifically, it pertains to an oral pharmaceutical composition containing Atovaquone, either alone or in combination with Proguanil, aimed at treating and preventing parasitic infections. Another significant patent involves the disclosure of complexes formed from antipneumocystic and antimalarial compounds, along with processes for their preparation and methods for utilizing these complexes in treating and preventing infections caused by parasites.
Career Highlights: Dharmendra Singh is an integral part of Ipca Laboratories Limited, where he plays a vital role in pharmaceutical innovation. His commitment to research and development has led to advancements that can significantly impact the effectiveness of treatments available in the market.
Collaborations: Throughout his career, Singh has collaborated with esteemed colleagues such as Ashok Kumar and Ganesh Devidas Mahale. These partnerships have enhanced his inventive process and fostered a collaborative environment for developing groundbreaking pharmaceutical solutions.
Conclusion: Dharmendra Singh represents a remarkable figure in the realm of pharmaceutical innovation. His numerous patents reflect a commitment to improving healthcare through advanced drug formulations and treatments for parasitic infections. As the industry continues to evolve, his ongoing work at Ipca Laboratories Limited is sure to contribute to significant advancements in pharmaceutical sciences.